Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
Alessandro Rossi, Michela Roberto, Martina Panebianco, et al.
European Journal of Pharmacology (2019) Vol. 862, pp. 172621-172621
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy
Peijie Zheng, Chuntao Zhou, Liuyi Lu, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 171
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4026-4026
Open Access | Times Cited: 56
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance
Joanna Pastwińska, Kaja Karaś, Iwona Karwaciak, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 4, pp. 188754-188754
Open Access | Times Cited: 42
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
Minjeong Yeon, Youngmi Kim, Hyun Suk Jung, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 52
Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
Liping Hu, Mengmeng Fan, Shengmin Shi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113963-113963
Closed Access | Times Cited: 46
Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer
Aditi Sharma, Lalit Sharma, Shouvik Kumar Nandy, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 750-750
Open Access | Times Cited: 18
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
Ewelina Dratkiewicz, Aleksandra Simiczyjew, Katarzyna Pietraszek‐Gremplewicz, et al.
International Journal of Molecular Sciences (2019) Vol. 21, Iss. 1, pp. 113-113
Open Access | Times Cited: 46
Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers
Jonas Béal, Lorenzo Pantolini, Vincent Noël, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 1, pp. e1007900-e1007900
Open Access | Times Cited: 35
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients withBRAF-Mutant Metastatic Non–Small Cell Lung Cancer
Sandra Ortiz-Cuarán, Laura Mezquita, Aurélie Swalduz, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 23, pp. 6242-6253
Open Access | Times Cited: 35
The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells
Silvia Peppicelli, Elena Andreucci, Jessica Ruzzolini, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 35, Iss. 1, pp. 1185-1193
Open Access | Times Cited: 29
Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
Ting Xu, Xicheng Wang, Zhenghang Wang, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 18
Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer
Maria Russi, Rachele Valeri, Domenico Marson, et al.
European Journal of Pharmaceutical Sciences (2022) Vol. 180, pp. 106311-106311
Open Access | Times Cited: 17
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Anaïs Paris, Nina Tardif, Maria Francesca Baietti, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 12
Open Access | Times Cited: 16
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Thibault Houlès, Geneviève Lavoie, Sami Nourreddine, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 16
Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy
Ali Talebi, Vincent de Laat, Xander Spotbeen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 10
Vemurafenib and Dabrafenib Downregulates RIPK4 Level
Ewelina Madej, Anna A. Brożyna, Agnieszka Adamczyk, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 918-918
Open Access | Times Cited: 9
Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas
Evelyn de Groot, Sruthy Varghese, Lin Tan, et al.
Cancer & Metabolism (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 14
BRAF inhibitors and their immunological effects in malignant melanoma
Rebecca Adams, Jack Coumbe, Ben G T Coumbe, et al.
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 4, pp. 347-362
Open Access | Times Cited: 13
Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
Jing Yu, Xi Wu, Jinen Song, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 13
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
Laura Soumoy, Corentin Schepkens, Mohammad Krayem, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1323-1323
Open Access | Times Cited: 18
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
Lauren G. Aoude, Vanessa Bonazzi, Sandra Brosda, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 17
BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells
Mariusz L. Hartman, Anna Gajos-Michniewicz, J.A. Talaj, et al.
Cancer Letters (2020) Vol. 499, pp. 122-136
Open Access | Times Cited: 16
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
Laurence Booth, Cameron West, Daniel D. Von Hoff, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 15
Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions
Rachel Fayne, Francisco Igor Macedo, Steven E. Rodgers, et al.
Oncology Reviews (2019) Vol. 13, Iss. 2
Open Access | Times Cited: 15
Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
Claudio Tabolacci, Martina Cordella, Sabrina Mariotti, et al.
Biomedicines (2021) Vol. 9, Iss. 1, pp. 79-79
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top